Specific PERK inhibitors enhanced glucose-stimulated insulin secretion in a mouse model of type 2 diabetes

Min Joo Kim, Mi Na Kim, Se Hee Min, Dong Sik Ham, Ji Won Kim, Kun Ho Yoon, Kyong Soo Park, Hye Seung Jung

Research output: Contribution to journalArticle

2 Scopus citations


Background: We have reported that partial PERK attenuation using PERK inhibitors (PI) enhanced glucose-stimulated insulin secretion (GSIS) from pancreatic islets and mice through induction of ER chaperone BIP. Therefore, we investigated if PI would have the same effects in a diabetic condition as well. Methods: GSK2606414 was treated to mouse islets under 20-mM glucose and 0.5-mM palmitate to examine GSIS. To generate a mouse model of type 2 diabetes mellitus (DM), male C57BL/6J mice were fed with high-fat diet and injected with streptozotocin. Several doses (6–16 mg/kg/day) of GSK2656157 and glimepiride were administrated to the mice for 8 weeks, and metabolic phenotypes were evaluated such as body weight, blood glucose levels, insulin secretion and sensitivity, and then changes in the pancreas were measured. Results: High-glucose and palmitate treatment significantly increased PERK phosphorylation in the isolated islets. Suppression of GSIS and glucose-stimulated Ca2+ transit was also observed. PI at 40 nM which decreased PERK phosphorylation by 40% significantly recovered the GSIS and cytosolic calcium. In the mice where significant weight gain and prominent hyperglycemia were induced, PI at 10 mg/kg/day significantly enhanced GSIS and reduced blood glucose levels compared to the vehicle. The effects were similar to those by 10 mg/kg/day of glimepiride. Administration of PI did not induce changes in beta cell mass or pancreatic insulin contents, however, high dose PI decreased pancreatic weight. Conclusion: PI at low dose significantly enhanced GSIS in vitro and in vivo under metabolic stress and improved hyperglycemia in the mice mimicking type 2 DM, suggesting a potential as a new therapeutic approach for type 2 DM.

Original languageEnglish
Pages (from-to)87-91
Number of pages5
JournalMetabolism: Clinical and Experimental
StatePublished - Aug 2019


  • Glucose-stimulated insulin secretion
  • PERK
  • PERK inhibitor
  • Type 2 diabetes mellitus

Fingerprint Dive into the research topics of 'Specific PERK inhibitors enhanced glucose-stimulated insulin secretion in a mouse model of type 2 diabetes'. Together they form a unique fingerprint.

  • Cite this